Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
As of today, Moderna(MRNA) shares are valued at $53.68. The company's market cap stands at 21.16B, with a P/E ratio of -7.38.
On 2026-02-28, Moderna(MRNA) stock traded between a low of $50.73 and a high of $53.70. Shares are currently priced at $53.68, which is +5.8% above the low and -0.0% below the high.
Moderna(MRNA) shares are trading with a volume of 9.07M, against a daily average of 10.24M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
MRNA News
Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketi...
In February 2026, Moderna’s mRNA-based seasonal flu vaccine application, initially rejected by the U.S. Food and Drug Administration over trial design concerns,...
The stock, after a few tough years, soared in the double-digits in January. Moderna (MRNA +0.46%) soared into the spotlight during the pandemic thanks to its m...
Analyst ratings
73%
of 26 ratingsMore MRNA News
The U.S. FDA is now reviewing Moderna’s mRNA flu vaccine application after previously issuing a Refusal to File tied to the study’s choice of comparator. This...
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweig...
Moderna made a fortune with COVID vaccines, but revenue has since declined. Moderna (MRNA +6.17%) became a household name during the coronavirus pandemic. Ther...
Piper Sandler raised the firm’s price target on Moderna (MRNA) to $69 from $63 and keeps an Overweight rating on the shares. The firm forecasts total product sa...
Moderna (MRNA) has disclosed a new risk, in the Debt & Financing category. Failure by Moderna to comply with covenants under its Ares Capital–led credit agreem...
Moderna ( (MRNA) ) has risen by 17.69%. Read on to learn why. President's Day Sale - 70% Off Unlock hedge fund-level data and powerful investing tools for smart...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.